The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.

We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (Johns Hopkins) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.

We also hear from Dr Suzanne Topalian (Johns Hopkins), Dr Antoni Ribas (UCLA) and Dr Pasi Jänne (Dana-Farber Cancer Institute).